Genmab Phase 3 interim death risk cut 50% in head and neck cancer

 

Genmab Phase 3 LiGeR-HN1 trial shows petosemtamab plus pembrolizumab cuts death risk 50% in first-line PD-L1+ recurrent/metastatic head and neck cancer

• Phase 3 LiGeR-HN1 met dual primary endpoints at the first interim analysis.
• Petosemtamab plus pembrolizumab reduced death risk 50% versus pembrolizumab alone in PD-L1+ recurrent/metastatic disease.
• Genmab plans to engage global regulators following the positive first-line head and neck cancer results.

https://finviz.com/stock?t=GMAB&p=d